A phase II study of higher dose docetaxel in androgen-independent prostate cancer.

Objectives: To assess the efficacy and toxicity profile of single agent docetaxel at a higher dose than previously evaluated in patients with androgen-independent prostate cancer (AIPC).

Patients And Methods: Patients with metastatic and progressive AIPC were treated with docetaxel 100 mg/m on day 1 of a 3-week cycle.

Results: Twenty-five patients with overt and rapid symptomatic deterioration from AIPC were entered into this study.